Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
- PMID: 33222700
- PMCID: PMC7682014
- DOI: 10.1186/s13024-020-00414-3
Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
Abstract
Introduction: Tau pathology is a major age-related event in Down syndrome with Alzheimer's disease (DS-AD). Although recently, several different Tau PET tracers have been developed as biomarkers for AD, these tracers showed different binding properties in Alzheimer disease and other non-AD tauopathies. They have not been yet investigated in tissue obtained postmortem for DS-AD cases. Here, we evaluated the binding characteristics of two Tau PET tracers (3H-MK6240 and 3H-THK5117) and one amyloid (3H-PIB) ligand in the medial frontal gyrus (MFG) and hippocampus (HIPP) in tissue from adults with DS-AD and DS cases with mild cognitive impairment (MCI) compared to sporadic AD.
Methods: Tau and amyloid autoradiography were performed on paraffin-embedded sections. To confirm respective ligand targets, adjacent sections were immunoreacted for phospho-Tau (AT8) and stained for amyloid staining using Amylo-Glo.
Results: The two Tau tracers showed a significant correlation with each other and with AT8, suggesting that both tracers were binding to Tau deposits. 3H-MK6240 Tau binding correlated with AT8 immunostaining but to a lesser degree than the 3H-THK5117 tracer, suggesting differences in binding sites between the two Tau tracers. 3H-THK5117, 3H-MK6240 and 3H-PIB displayed dense laminar binding in the HIPP and MFG in adult DS brains. A regional difference in Tau binding between adult DS and AD was observed suggesting differential regional Tau deposition in adult DS compared to AD, with higher THK binding density in the MFG in adult with DS compared to AD. No significant correlation was found between 3H-PIB and Amylo-Glo staining in adult DS brains suggesting that the amyloid PIB tracer binds to additional sites.
Conclusions: This study provides new insights into the regional binding distribution of a first-generation and a second-generation Tau tracer in limbic and neocortical regions in adults with DS, as well as regional differences in Tau binding in adult with DS vs. those with AD. These findings provide new information about the binding properties of two Tau radiotracers for the detection of Tau pathology in adults with DS in vivo and provide valuable data regarding Tau vs. amyloid binding in adult DS compared to AD.
Keywords: Alzheimer’s disease; Down syndrome; Neurofibrillary tangles; Neuropathology; PET tracers.
Conflict of interest statement
The authors do not report any conflicts of interest.
Figures




Similar articles
-
Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer's disease cases.Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1093-1102. doi: 10.1007/s00259-020-05035-y. Epub 2020 Sep 24. Eur J Nucl Med Mol Imaging. 2021. PMID: 32970217 Free PMC article.
-
Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.Mol Psychiatry. 2023 Mar;28(3):1272-1283. doi: 10.1038/s41380-022-01875-2. Epub 2022 Nov 29. Mol Psychiatry. 2023. PMID: 36447011 Free PMC article.
-
Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography.Sci Rep. 2017 Apr 4;7:45496. doi: 10.1038/srep45496. Sci Rep. 2017. PMID: 28374768 Free PMC article.
-
Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome.Dev Neurobiol. 2019 Jul;79(7):711-715. doi: 10.1002/dneu.22658. Epub 2018 Dec 16. Dev Neurobiol. 2019. PMID: 30536948 Review.
-
The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.Biomolecules. 2023 Feb 3;13(2):290. doi: 10.3390/biom13020290. Biomolecules. 2023. PMID: 36830659 Free PMC article. Review.
Cited by
-
USP25 inhibition ameliorates Alzheimer's pathology through the regulation of APP processing and Aβ generation.J Clin Invest. 2022 Mar 1;132(5):e152170. doi: 10.1172/JCI152170. J Clin Invest. 2022. PMID: 35229730 Free PMC article.
-
The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome.J Clin Med. 2024 Feb 27;13(5):1338. doi: 10.3390/jcm13051338. J Clin Med. 2024. PMID: 38592182 Free PMC article. Review.
-
Charting the future: current and future directions in translational research for individuals with Down syndrome.J Neurodev Disord. 2025 Jul 8;17(1):38. doi: 10.1186/s11689-025-09630-8. J Neurodev Disord. 2025. PMID: 40629284 Free PMC article. Review.
-
Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome.Acta Neuropathol Commun. 2022 Jun 8;10(1):86. doi: 10.1186/s40478-022-01385-w. Acta Neuropathol Commun. 2022. PMID: 35676735 Free PMC article.
-
Postnatal Cytoarchitecture and Neurochemical Hippocampal Dysfunction in Down Syndrome.J Clin Med. 2021 Jul 31;10(15):3414. doi: 10.3390/jcm10153414. J Clin Med. 2021. PMID: 34362198 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical